MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Clinical Compound Library Plus

MCE 站：Clinical Compound Library Plus

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re?tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing.MCE owns a unique collection of 1492 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Description & Advantages:

?   A unique collection of 1492 clinical compounds for high throughput screening (HTS) and high content screening (HCS).

?   Research areas include anticancer, anti-infection, anti inflammation, nervous disease, and more.

?   A useful tool for drug repurposing.

?   Currently in clinical stage, some are withdrawn or terminated.

?   Structurally diverse, medicinally active, and cell permeable.

?   Detailed compound information with structure, IC₅₀, and brief introduction.

?   Validated NMR and HPLC to ensure high purity and quality.

?   All compounds are in stock and continuously updated.

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。